Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals?
Abdolvahab Ebrahimpour GorjiPiotr OstaszewskiKaja UrbańskaTomasz SadkowskiPublished in: Biomedicines (2023)
Skeletal muscle is the protein reservoir of our body and an important regulator of glucose and lipid homeostasis. The dystrophin gene is the largest gene and has a key role in skeletal muscle construction and function. Mutations in the dystrophin gene cause Duchenne and Becker muscular dystrophy in humans, mice, dogs, and cats. Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular condition causing progressive muscle weakness and premature death. β-hydroxy β-methylbutyrate (HMB) prevents deleterious muscle responses under pathological conditions, including tumor and chronic steroid therapy-related muscle losses. The use of HMB as a dietary supplement allows for increasing lean weight gain; has a positive immunostimulatory effect; is associated with decreased mortality; and attenuates sarcopenia in elderly animals and individuals. This study aimed to identify some genes, metabolic pathways, and biological processes which are common for DMD and HMB based on existing literature and then discuss the consequences of that interaction.
Keyphrases
- duchenne muscular dystrophy
- muscular dystrophy
- skeletal muscle
- weight gain
- genome wide
- genome wide identification
- insulin resistance
- copy number
- body mass index
- systematic review
- birth weight
- multiple sclerosis
- transcription factor
- type diabetes
- stem cells
- dna methylation
- human health
- blood pressure
- adipose tissue
- mouse model
- cardiovascular events
- metabolic syndrome
- replacement therapy
- gene expression
- climate change
- weight loss
- bone marrow
- combination therapy
- wild type